Neuronal nicotinic acetylcholine receptors: From the genetic analysis to neurological diseases

Biochemical Pharmacology

Volumn 76, Issue 10, 2008, Pages 1175-1183

  Steinlein, O K ^a   Bertrand, D ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINIC RECEPTOR;

ALZHEIMER DISEASE; ARTICLE; CENTRAL NERVOUS SYSTEM; EPILEPSY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOME; NERVE CELL; NEUROTRANSMISSION; PRIORITY JOURNAL; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 54049101939     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.07.012     Document Type: Note

References (78)

1. Kawashima K., and Fujii T. Basic and clinical aspects of non-neuronal acetylcholine: overview of non-neuronal cholinergic systems and their biological significance. J Pharmacol Sci 106 (2008) 167-173
2. Ulloa L. The vagus nerve and the nicotinic anti-inflammatory pathway. Nat Rev Drug Discov 4 (2005) 673-684
3. Engel A.G., and Sine S.M. Current understanding of congenital myasthenic syndromes. Curr Opin Pharmacol 5 (2005) 308-321
4. Steinlein O.K. Human disorders caused by the disruption of the regulation of excitatory neurotransmission. Results Probl Cell Differ 44 (2008) 223-242
5. Steinlein O.K. Genetic disorders caused by mutated acetylcholine receptors. Life Sci 80 (2007) 2186-2190
6. Southan C. Has the yo-yo stopped? An assessment of human protein-coding gene number. Proteomics 4 (2004) 1712-1726
7. Knight J.C. Functional implications of genetic variation in non-coding DNA for disease susceptibility and gene regulation. Clin Sci (Lond) 104 (2003) 493-501
8. Haiman C.A., and Stram D.O. Utilizing HapMap and tagging SNPs. Methods Mol Med 141 (2008) 37-54
9. Bodmer W., and Bonilla C. Common and rare variants in multifactorial susceptibility to common diseases. Nat Genet 40 (2008) 695-701
10. Wallace H.M. A model of gene-gene and gene-environment interactions and its implications for targeting environmental interventions by genotype. Theor Biol Med Model 3 (2006) 35
11. Ioannidis J.P., Trikalinos T.A., and Khoury M.J. Implications of small effect sizes of individual genetic variants on the design and interpretation of genetic association studies of complex diseases. Am J Epidemiol 16 (2006) 609-614
12. Hirschhorn J.N., Lohmueller K., Byrne E., and Hirschhorn K. A comprehensive review of genetic association studies. Genet Med 4 (2002) 45-61
13. Manolio T.A., Brooks L.D., and Collins F.S. A HapMap harvest of insights into the genetics of common disease. J Clin Invest 118 (2008) 1590-1605
14. Duga S., Soldà G., Asselta R., Bonati M.T., Dalprà L., Malcovati M., et al. Characterization of the genomic structure of the human neuronal nicotinic acetylcholine receptor CHRNA5/A3/B4 gene cluster and identification of novel intragenic polymorphisms. J Hum Genet 46 (2001) 640-648
15. Tishkoff S.A., and Verrelli B.C. Role of evolutionary history on haplotype block structure in the human genome: implications for disease mapping. Curr Opin Genet Dev 13 (2003) 569-575
16. van den Oord E.J., and Neale B.M. Will haplotype maps be useful for finding genes?. Mol Psychiatry 9 (2004) 227-236
17. Wessler I., Kilbinger H., Bittinger F., Unger R., and Kirkpatrick C.J. The non-neuronal cholinergic system in humans: expression, function and pathophysiology. Life Sci 72 (2003) 2055-2061
18. Cooper E., Couturier S., and Ballivet M. Pentameric structure and subunit stoichiometry of a neuronal nicotinic acetylcholine receptor. Nature 350 (1991) 235-238
19. Gotti C., Zoli M., and Clementi F. Brain nicotinic acetylcholine receptors: native subtypes and their relevance. Trends Pharmacol Sci 27 (2006) 482-491
20. Kuryatov A., Onksen J., and Lindstrom J. Roles of accessory subunits in {alpha}4{beta}2* nicotinic receptors. Mol Pharmacol 74 (2008) 132-143
21. Jones I.W., and Wonnacott S. Why doesn't nicotinic ACh receptor immunoreactivity knock out?. Trends Neurosci 28 (2005) 343-345
22. Moser N., Mechawar N., Jones I., Gochberg-Sarver A., Orr-Urtreger A., Plomann M., et al. Evaluating the suitability of nicotinic acetylcholine receptor antibodies for standard immunodetection procedures. J Neurochem 102 (2007) 479-492
23. Han Z.Y., Le Novere N., Zoli M., Hill Jr. J.A., Champtiaux N., and Changeux J.P. Localization of nAChR subunit mRNAs in the brain of Macaca mulatta. Eur J Neurosci 12 (2000) 3664-3674
24. Gotti C., Moretti M., Gaimarri A., Zanardi A., Clementi F., and Zoli M. Heterogeneity and complexity of native brain nicotinic receptors. Biochem Pharmacol 74 (2007) 1102-1111
25. Vincler M.A., and Eisenach J.C. Immunocytochemical localization of the alpha3, alpha4, alpha5, alpha7, beta2, beta3 and beta4 nicotinic acetylcholine receptor subunits in the locus coeruleus of the rat. Brain Res 974 (2003) 25-36
26. Quik M., Polonskaya Y., Gillespie A., Jakowec M., Lloyd G.K., and Langston J.W. Localization of nicotinic receptor subunit mRNAs in monkey brain by in situ hybridization. J Comp Neurol 425 (2000) 58-69
27. Torrão A.S., Lindstrom J.M., and Britto L.R. Distribution of the alpha 2, alpha 3, and alpha 5 nicotinic acetylcholine receptor subunits in the chick brain. Braz J Med Biol Res 30 (1997) 1209-1213
28. Göldner F.M., Dineley K.T., and Patrick J.W. Immunohistochemical localization of the nicotinic acetylcholine receptor subunit alpha6 to dopaminergic neurons in the substantia nigra and ventral tegmental area. Neuroreport 8 (1997) 2739-2742
29. Britto L.R., Keyser K.T., Lindstrom J.M., and Karten H.J. Immunohistochemical localization of nicotinic acetylcholine receptor subunits in the mesencephalon and diencephalon of the chick (Gallus gallus). J Comp Neurol 317 (1992) 325-340
30. Lam D.C., Girard L., Ramirez R., Chau W.S., Suen W.S., Sheridan S., et al. Expression of nicotinic acetylcholine receptor subunit genes in non-small-cell lung cancer reveals differences between smokers and nonsmokers. Cancer Res 67 (2007) 4638-4648
31. Tournier J.M., Maouche K., Coraux C., Zahm J.M., Cloëz-Tayarani I., Nawrocki-Raby B., et al. alpha3alpha5beta2-nicotinic acetylcholine receptor contributes to the wound repair of the respiratory epithelium by modulating intracellular calcium in migrating cells. Am J Pathol 168 (2006) 55-68
32. Carlisle D.L., Hopkins T.M., Gaither-Davis A., Silhanek M.J., Luketich J.D., Christie N.A., et al. Nicotine signals through muscle-type and neuronal nicotinic acetylcholine receptors in both human bronchial epithelial cells and airway fibroblasts. Respir Res 5 (2004) 27
33. Grando S.A. Basic and clinical aspects of non-neuronal acetylcholine: biological and clinical significance of non-canonical ligands of epithelial nicotinic acetylcholine receptors. J Pharmacol Sci 106 (2008) 174-179
34. Placzek A.N., Grassi F., Papke T., Meyer E.M., and Papke R.L. A single point mutation confers properties of the muscle-type nicotinic acetylcholine receptor to homomeric alpha7 receptors. Mol Pharmacol 66 (2004) 169-177
35. Steinlein O.K., Mulley J.C., Propping P., Wallace R.H., Phillips H.A., Sutherland G.R., et al. A missense mutation in the neuronal nicotinic acetylcholine receptor alpha 4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy. Nat Genet 11 (1995) 201-203
36. Scheffer I.E., Bhatia K.P., Lopes-Cendes I., Fish D.R., Marsden C.D., Andermann E., et al. Autosomal dominant nocturnal frontal lobe epilepsy. A distinctive clinical disorder. Brain 118 (1995) 61-73
37. Provini F., Plazzi G., Montagna P., and Lugaresi E. The wide clinical spectrum of nocturnal frontal lobe epilepsy. Sleep Med Rev 4 (2000) 375-386
38. Leniger T., Kananura C., Hufnagel A., Bertrand S., Bertrand D., and Steinlein O.K. A new Chrna4 mutation with low penetrance in nocturnal frontal lobe epilepsy. Epilepsia 44 (2003) 981-985
39. Hirose S., Iwata H., Akiyoshi H., Kobayashi K., Ito M., Wada K., et al. A novel mutation of CHRNA4 responsible for autosomal dominant nocturnal frontal lobe epilepsy. Neurology 53 (1999) 1749-1753
40. De Fusco M., Becchetti A., Patrignani A., Annesi G., Gambardella A., Quattrone A., et al. The nicotinic receptor beta 2 subunit is mutant in nocturnal frontal lobe epilepsy. Nat Genet 26 (2000) 275-276
41. Phillips H.A., Favre I., Kirkpatrick M., Zuberi S.M., Goudie D., Heron S.E., et al. CHRNB2 is the second acetylcholine receptor subunit associated with autosomal dominant nocturnal frontal lobe epilepsy. Am J Hum Genet 68 (2001) 225-231
42. Bertrand D., Elmslie F., Hughes E., Trounce J., Sander T., Bertrand S., et al. The CHRNB2 mutation I312M is associated with epilepsy and distinct memory deficits. Neurobiol Dis 20 (2005) 799-804
43. Hoda J.C., Gu W., Friedli M., Phillips H., Bertrand S., Antonarakis S.E., et al. Human nocturnal frontal lobe epilepsy: pharmocogenomic profiles of pathogenic nAChR {beta}-subunit mutations outside the ion channel pore. Mol Pharmacol 74 (2008) 379-391
44. Cho Y.W., Motamedi G.K., Laufenberg I., Sohn S.I., Lim J.G., Lee H., et al. A Korean kindred with autosomal dominant nocturnal frontal lobe epilepsy and mental retardation. Arch Neurol 60 (2003) 1625-1632
45. Magnusson A., Stordal E., Brodtkorb E., and Steinlein O. Schizophrenia, psychotic illness and other psychiatric symptoms in families with autosomal dominant nocturnal frontal lobe epilepsy caused by different mutations. Psychiatr Genet 13 (2003) 91-95
46. Itier V., and Bertrand D. Mutations of the neuronal nicotinic acetylcholine receptors and their association with ADNFLE. Neurophysiol Clin 32 (2002) 99-107
47. Rodrigues-Pinguet N., Jia L., Li M., Figl A., Klaassen A., Truong A., et al. Five ADNFLE mutations reduce the Ca2+ dependence of the mammalian alpha4beta2 acetylcholine response. J Physiol 550 (2003) 11-26
48. Mann E.O., and Mody I. The multifaceted role of inhibition in epilepsy: seizure-genesis through excessive GABAergic inhibition in autosomal dominant nocturnal frontal lobe epilepsy. Curr Opin Neurol 21 (2008) 155-160
49. Ponomarev I., Maiya R., Harnett M.T., Schafer G.L., Ryabinin A.E., Blednov Y.A., et al. Transcriptional signatures of cellular plasticity in mice lacking the alpha1 subunit of GABAA receptors. J Neurosci 26 (2006) 5673-5683
50. Teper Y., Whyte D., Cahir E., Lester H.A., Grady S.R., Marks M.J., et al. Nicotine-induced dystonic arousal complex in a mouse line harboring a human autosomal-dominant nocturnal frontal lobe epilepsy mutation. J Neurosci 27 (2007) 10128-10142
51. Klaassen A., Glykys J., Maguire J., Labarca C., Mody I., and Boulter J. Seizures and enhanced cortical GABAergic inhibition in two mouse models of human autosomal dominant nocturnal frontal lobe epilepsy. Proc Natl Acad Sci USA 103 (2006) 19152-19157
52. Aridon P., Marini C., Di Resta C., Brilli E., De Fusco M., Politi F., et al. Increased sensitivity of the neuronal nicotinic receptor alpha 2 subunit causes familial epilepsy with nocturnal wandering and ictal fear. Am J Hum Genet 79 (2006) 342-350
53. Combi R, Ferini-Strambi L, Tenchini L. CHRNA2 mutations are rare in the NFLE population: evaluation of a large cohort of Italian patients. Sleep Med Rev doi:10.1016/j.sleep.2007.11.010.
54. Gu W., Bertrand D., and Steinlein O.K. A major role of the nicotinic acetylcholine receptor gene CHRNA2 in autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) is unlikely. Neurosci Lett 422 (2007) 74-76
55. Winterer G., Musso F., Konrad A., Vucurevic G., Stoeter P., Sander T., et al. Association of attentional network function with exon 5 variations of the CHRNA4 gene. Hum Mol Genet 16 (2007) 2165-2174
56. Cook L.J., Ho L.W., Taylor A.E., Brayne C., Evans J.G., Xuereb J., et al. Candidate gene association studies of the alpha 4 (CHRNA4) and beta 2 (CHRNB2) neuronal nicotinic acetylcholine receptor subunit genes in Alzheimer's disease. Neurosci Lett 358 (2004) 142-146
57. Dorszewska J., Florczak J., Rozycka A., Jaroszewska-Kolecka J., Trzeciak W.H., and Kozubski W. Polymorphisms of the CHRNA4 gene encoding the alpha4 subunit of nicotinic acetylcholine receptor as related to the oxidative DNA damage and the level of apoptotic proteins in lymphocytes of the patients with Alzheimer's disease. DNA Cell Biol 24 (2005) 786-794
58. Li M.D., Sun D., Lou X.Y., Beuten J., Payne T.J., and Ma J.Z. Linkage and association studies in African- and Caucasian-American populations demonstrate that SHC3 is a novel susceptibility locus for nicotine dependence. Mol Psychiatry 12 (2007) 462-473
59. Hutchison K.E., Allen D.L., Filbey F.M., Jepson C., Lerman C., Benowitz N.L., et al. CHRNA4 and tobacco dependence: from gene regulation to treatment outcome. Arch Gen Psychiatry 64 (2007) 1078-1086
60. Hung R.J., McKay J.D., Gaborieau V., Boffetta P., Hashibe M., Zaridze D., et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 452 (2008) 633-637
61. Saccone S.F., Hinrichs A.L., Saccone N.L., Chase G.A., Konvicka K., Madden P.A., et al. Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum Mol Genet 16 (2007) 36-49
62. Amos C.I., Wu X., Broderick P., Gorlov I.P., Gu J., Eisen T., et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet 40 (2008) 616-622
63. Thorgeirsson T.E., Geller F., Sulem P., Rafnar T., Wiste A., Magnusson K.P., et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 452 (2008) 638-642
64. Ramirez-Latorre J., Yu C.R., Qu X., Perin F., Karlin A., and Role L. Functional contributions of alpha5 subunit to neuronal acetylcholine receptor channels. Nature 380 (1996) 347-351
65. Salminen O., Murphy K.L., McIntosh J.M., Drago J., Marks M.J., Collins A.C., et al. Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice. Mol Pharmacol 65 (2004) 1526-1535
66. Sher E., Codignola A., Passafaro M., Tarroni P., Magnelli V., Carbone E., et al. Nicotinic receptors and calcium channels in small cell lung carcinoma. Functional role, modulation, and autoimmunity. Ann N Y Acad Sci 841 (1998) 606-624
67. Song P., and Spindel E.R. Basic and clinical aspects of non-neuronal acetylcholine: expression of non-neuronal acetylcholine in lung cancer provides a new target for cancer therapy. J Pharmacol Sci 106 (2008) 180-185
68. Tarroni P., Rubboli F., Chini B., Zwart R., Oortgiesen M., Sher E., et al. Neuronal-type nicotinic receptors in human neuroblastoma and small-cell lung carcinoma cell lines. FEBS Lett 312 (1992) 66-70
69. Freedman R., Coon H., Myles-Worsley M., Orr-Urtreger A., Olincy A., Davis A., et al. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci USA 94 (1997) 587-592
70. Raux G., Bonnet-Brilhault F., Louchart S., Houy E., Gantier R., Levillain D., et al. The -2 bp deletion in exon 6 of the 'alpha 7-like' nicotinic receptor subunit gene is a risk factor for the P50 sensory gating deficit. Mol Psychiatry 7 (2002) 1006-1011
71. Leonard S., Gault J., Hopkins J., Logel J., Vianzon R., Short M., et al. Association of promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia. Arch Gen Psychiatry 59 (2002) 1085-1096
72. Martin L.F., Leonard S., Hall M.H., Tregellas J.R., Freedman R., and Olincy A. Sensory gating and alpha-7 nicotinic receptor gene allelic variants in schizoaffective disorder, bipolar type. Am J Med Genet B Neuropsychiatr Genet 144B (2007) 611-614
73. Breese C.R., Lee M.J., Adams C.E., Sullivan B., Logel J., Gillen K.M., et al. Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology 23 (2000) 351-364
74. Houy E., Raux G., Thibaut F., Belmont A., Demily C., Allio G., et al. The promoter -194C polymorphism of the nicotinic alpha 7 receptor gene has a protective effect against the P50 sensory gating deficit. Mol Psychiatry 9 (2004) 320-322
75. De Luca V., Wong A.H., Muller D.J., Wong G.W., Tyndale R.F., and Kennedy J.L. Evidence of association between smoking and alpha7 nicotinic receptor subunit gene in schizophrenia patients. Neuropsychopharmacology 29 (2004) 1522-1526
76. Stassen H.H., Bridler R., Hagele S., Hergersberg M., Mehmann B., Schinzel A., et al. Schizophrenia and smoking: evidence for a common neurobiological basis?. Am J Med Genet 96 (2000) 173-177
77. Gault J., Robinson M., Berger R., Drebing C., Logel J., Hopkins J., et al. Genomic organization and partial duplication of the human alpha7 neuronal nicotinic acetylcholine receptor gene (CHRNA7). Genomics 52 (1998) 173-185
78. Olincy A., Harris J.G., Johnson L.L., Pender V., Kongs S., Allensworth D., et al. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 63 (2006) 630-638